Bristol-Myers Squibb Slaps Lawsuit On Biotech Pioneer Genentech Over Cancer Immunotherapy Patents

Published: Jul 27, 2017

Drug giant Bristol-Myers Squibb Co. filed suit Wednesday against biotech pioneer Genentech Inc., saying the South San Francisco company infringed patents in developing a potential blockbuster cancer immunotherapy drug.

Bristol-Myers Squibb (NYSE: BMY) seeks unspecified damages in the suit, filed in U.S. District Court in Delaware. At stake are sales of potentially billions of dollars worth of cancer drugs.

Back to news